GSK Reports the US FDA Approval of Penmenvy (MenABCWY Vaccine) for Protection Against Invasive Meningococcal Disease (IMD)

Shots:

• The US FDA has approved Penmenvy for individuals (10-25yrs) to protect against 5 serogroups of N. meningitidis (A, B, C, W, & Y) responsible for IMD. Meanwhile, the CDC’s ACIP will vote on Feb 26, 2025, to recommend the use of Penmenvy in adolescents & young adults
• Approval was supported by 2 P-III trials (2019-001666-15 & 2019-004982-42) assessing the vaccine’s safety, tolerability, & immune response in ~4800 subjects (10-25yrs.) that showed consistent safety
• Penmenvy integrates antigenic properties of lyophilized Menveo (MenACWY vaccine), which is reconstituted using a prefilled syringe of liquid Bexsero (MenB Vaccine)

Ref: GSK  | Image: GSK

Related News:- The EMA Accepts MAA for GSK’s Depemokimab as an Adjunctive to Treat Asthma with Type 2 Inflammation and CRSwNP

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com